1-8 of 8
Matthew Foster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Free
Hanny Al-Samkari, Adam Cuker, Francesco Zaja, Marc Michel, Waleed Ghanima, Thomas Stauch, Lei Zhang, Ming Hou, Thomas Zander, Azizan Sharif, Jing Sun, Prof. Uttam Kumar Nath, Roger Schutgens, Elena Rossi, Lien Deleu, Libor Červinek, Jae-Ho Yoon, Hung Chang, Theera Ruchutrakool, Masaki Iino, Tatsunori Goto, Patrick Urban, Justyna Fronczek, Matthew Foster, Marine Weill, Nicola Cooper
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-2.
https://doi.org/10.1182/blood-2025-LBA-2
Published: 2025
Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Free
Pere Barba, Alessandro Rambaldi, Nicolas Boissel, Noriko Doki, Didier Blaise, Fabio Ciceri, Javier Briones Meijide, Mi Kwon, Shaun Fleming, Cristina Blázquez Goñi, Takanori Teshima, Koji Kato, Marie Balsat, Ulrich Jaeger, Leyla Shune, Pedro Marques Ramos, David Pearson, James Corcoran, Aiesha Zia, Matthew Foster, Aisha Masood, Michael Dickinson
Journal: Blood
Blood (2025) 146 (Supplement 1): 811.
https://doi.org/10.1182/blood-2025-811
Published: 2025
Journal Articles

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Free
Francesco Zaja, Adam Cuker, Hanny Al-Samkari, Marc Michel, Yogesh Chattar, Matthew Foster, Meritxell Vendranas, Nicola Cooper
Journal: Blood
Blood (2025) 146 (Supplement 1): 6586.
https://doi.org/10.1182/blood-2025-6586
Published: 2025
Journal Articles

Personalized and Optimized Low-Dose and Intensive Chemotherapy Treatments for Patients with Acute Myeloid Leukemia (AML)

Free
Ana Luz Quiroga-Campano, PhD MSc, BSc, Louise Enfield, Matthew Foster, BS, Margaritis Kostoglou, PhD, Michael Georgiadis, PhD, Athanasios Mantalaris, PhD, Nicki Panoskaltsis, MD PhD FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 3500.
https://doi.org/10.1182/blood-2018-99-119258
Published: 2018
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Free
Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017
Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Free
Kenneth Jacobs, MD, John Godwin, MD, Matthew Foster, Norbert Vey, Geoffrey L. Uy, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P Rettig, PhD, Stephanie Christ, MS, Max S. Topp, MD, Geert Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Jichao Sun, PhD, Daner Li, MS, Kathy Tran, Karen Spohn, BS, Jan Baughman, MPH, Sadhna Shankar, MDMPH, Helene Lelièvre, PhD PharmD, Ezio Bonvini, MD, John F DiPersio, MD PhD, Jon Wigginton, Jan K davidson-Moncada, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3856.
https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856
Published: 2017
Journal Articles

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Free
Tara L. Lin, MD, Geoffrey L. Uy, MD, Matthew J. Wieduwilt, Laura F. Newell, MD, Robert K. Stuart, MD, Bruno C Medeiros, MD, Gary J. Schiller, Eric Rubenstein, MD, Wendy Stock, MD, Erica D. Warlick, MD, Matthew Foster, Dale L. Bixby, Nikolai A. Podoltsev, MD PhD, Qi An, Stefan Faderl, Arthur C. Louie, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1698.
https://doi.org/10.1182/blood.V130.Suppl_1.1698.1698
Published: 2017
Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Free
Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1349.
https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349
Published: 2017